AbbVie Stock Plummets After Schizophrenia Drug Trials Fail

AbbVie's emraclidine failed to meet key endpoints in Phase 2 trials, impacting its $8.7 billion acquisition of Cerevel Therapeutics.

AbbVie's emraclidine did not show significant improvement in schizophrenia symptoms compared to a placebo in two Phase 2 trials.
The disappointing trial results led to a 12% drop in AbbVie's stock, marking its largest decline in over four years.
Bristol Myers Squibb's shares surged as its recently approved schizophrenia drug, Cobenfy, benefited from AbbVie's setback.
Analysts had anticipated positive outcomes from AbbVie's trials, but the failure raises questions about selective muscarinic targeting for schizophrenia.
Despite the setback, AbbVie remains committed to analyzing the data and exploring potential next steps for its schizophrenia treatment.